We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Aortech International Plc | LSE:AOR | London | Ordinary Share | GB0033360586 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 126.50 | 123.00 | 130.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
31/8/2018 08:09 | Some tried to monkey hammer the price to form the H&S yesterday, really bullish reversal from the low sets up the assault to 100p plus IMO. | greedy rooster | |
30/8/2018 13:17 | Clive Titcomb, Founder in 1986 and serves as a Director and the Chief Executive Officer of Astrac Limited. Mr. Titcomb works closely with ASTRAC's Managing Director, Rob Cobley, and the management team in driving the rapid expansion of ASTRAC's business. Mr. Titcomb is responsible for ASTRAC's overall mission and future strategy. In addition, he continues to build on ASTRAC's successful long-term and world-wide relationship with the IBM Corporation as well as developing strategic partnerships with technology providers in the Business Intelligence and related softwares sector. Mr. Titcomb firmly advocates that for an organisation to achieve long-term success then senior management must maintain and develop close partnerships with Customers at all levels. This is why he also takes responsibility for and works directly with several of ASTRAC's Customers and why ASTRAC has a clear understanding of its Customers' and future Customers' needs. Prior to this Mr. Titcomb's responsibilities ranged from marketing and market research at IBM to delivery management of Management Information and Data Warehousing solutions for major IBM customers. Clive's gained valuable previous experience when working with a global consulting organisation as well as a financial role within an international marketing business. He has a professional background in both finance and marketing disciplines. | the stigologist | |
30/8/2018 13:06 | Yes, Landy90, I believe a few of us did the same! | bones | |
30/8/2018 13:03 | Cheers Bones. The more I look into this co. the more I like it. Can't see it staying this low for too long. | someuwin | |
30/8/2018 12:30 | Or Clive took advice from this Board and bought the dips on 20 August. But bought in size. | landy90 | |
30/8/2018 12:13 | Clive Titcomb is a long time holder, probably well connected and knowledgable in AOR circles and happily accumulating it seems. | bones | |
30/8/2018 12:09 | p.s I think this will tick up again soon. | someuwin | |
30/8/2018 12:05 | Yes - I don't know who he is. But clearly a smart investor. | someuwin | |
30/8/2018 11:57 | someuwin. I saw that. A very positive sign. | investordave | |
30/8/2018 11:43 | TRIX has just turned positive always a good sign when its at the bottom steve. | blueball | |
30/8/2018 11:37 | Holdings RNS Clive Titcomb and family increase holding from 4.04% to 5.17% | someuwin | |
30/8/2018 11:13 | Buy those dips Sir! Guys keep an eye on (IDP) operations update due Monday, should be pretty active. Dyor as usual I am expecting a break into 100p’s in Q4 if all goes well with further positive newsflow | ny boy | |
30/8/2018 11:08 | Good advice once again blueball price coming back strongly now. Some decent buys this morning | steveallen | |
30/8/2018 10:36 | An update of the development stages would be nice but I agree it needs time. | zoro9791 | |
30/8/2018 10:21 | Found the following (from back in June this year) on AOR's new partner Vascular Flow Technologies' website. All sounding very positive... "Agreement to Develop Synthetic Heart Valve - We are delighted to be working with AorTech on a project which involves detailed computational modelling and analysis of AorTech’s synthetic heart valve with the aim of further design optimisation, manufacturing and testing. It is hoped the work will lead to the first ‘in man’ testing of the technology. Craig Dunlop, General Manager and director of VFT, said: “The team at VFT has been very impressed with the quantity and quality of data that AorTech has been able to demonstrate to us. “We are very excited to be a key partner in the development of the next generation of prosthetic heart valves which should represent not only a step change in performance, but dramatically reduce the cost to manufacture these life enhancing devices.” Bill Brown, chairman of Surrey-based AorTech, said his company now had access to Europe’s leading experts in the combined field of “medical imaging, guided finite element analysis and computational fluid dynamics”. He added: “Combining the design history with this ground breaking imaging analysis should much improve the quality of the product design, reliability and performance.” | someuwin | |
30/8/2018 09:44 | Zoro What type of proper news are you looking for, this company is developing medical devices which takes a while? | landy90 | |
30/8/2018 09:18 | Can't buy any online. | someuwin | |
30/8/2018 09:14 | Buy on the dips.. | blueball | |
30/8/2018 08:57 | ID - a man has got to eat. | bones | |
30/8/2018 08:56 | And looks like just small shareholders. Nothing to be concerned about. | investordave | |
30/8/2018 08:56 | Blimey I was really hopefully that we will recover. Can't blame the traders to look elsewhere. It's all about the money. | zoro9791 | |
30/8/2018 08:50 | They probably need some cash for the weekly shop bones. | investordave | |
30/8/2018 08:49 | Short term punters taking their £500 profits. Let them sell I say! | bones |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions